湖南启元律师事务所 法律意见书 湖南启元律师事务所 关于湖南九典制药股份有限公司 2025年第一次临时股东会的 法律意见书 二〇二五年九月 湖南省长沙市芙蓉区建湘路393号世茂环球金融中心63层 电话： 0731-8295 3778传真：0731-8295 3779 网站： www.qiyuan.com 湖南启元律师事务所 法律意见书 湖南启元律师事务所 关于湖南九典制药股份有限公司 2025 年第一次临时股东会的 法律意见书 致：湖南九典制药股份有限公司 湖南启元律师事务所（以下简称"本所"）接受湖南九典制药股份有限公司（以 下简称"公司"）的委托，指派本所律师出席了公司2025年第一次临时股东会（以 下简称"本次股东会"），对本次股东会的召集和召开程序、出席会议人员及召集 人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发表本法律 意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《湖南九典 制药股份有限公司章程》（以下简称"《公 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-065 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于九典转 02 付息的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、九典转02（债券代码：123223）将于2025年9月15日按面值支付第二年利 息，每10张九典转02（面值1,000元）利息为5.00元（含税）。 2、债权登记日：2025年9月12日（星期五） 8、下一年度的票面利率：1.00% 湖南九典制药股份有限公司（以下简称"公司"）于2023年9月15日向不特定 对象发行的可转换公司债券将于2025年9月15日支付2024年9月15日至2025年9月 14日的利息，根据《湖南九典制药股份有限公司创业板向不特定对象发行可转换 公司债券募集说明书》（以下简称《募集说明书》）有关条款的规定，现将本次付 息有关事项公告如下： 一、九典转02的基本情况 1、可转债中文简称：九典转 02 3、付息日：2025年9月15日（ ...

Core Viewpoint - Jiutian Pharmaceutical (300705.SZ) announced a share buyback program, indicating a commitment to enhancing shareholder value through capital return strategies [1] Summary by Categories Share Buyback Details - As of August 31, 2025, the company has repurchased a total of 6,180,800 shares, which represents 1.24% of the current total share capital [1] - The highest transaction price during the buyback was 18.44 CNY per share, while the lowest was 14.51 CNY per share [1] - The total amount spent on the buyback reached 100 million CNY, excluding transaction fees [1]

Group 1 - The company, Jiutian Pharmaceutical, announced a share buyback of approximately 6.18 million shares, accounting for 1.24% of its total share capital, with a total transaction amount of about 100 million yuan [1][1][1] - The highest transaction price during the buyback was 18.44 yuan per share, while the lowest was 14.51 yuan per share [1][1][1] - As of the report, Jiutian Pharmaceutical has a market capitalization of 9.5 billion yuan [1][1][1] Group 2 - For the first half of 2025, the revenue composition of Jiutian Pharmaceutical is as follows: 82.47% from pharmaceutical preparations, 7.65% from raw materials, 6.03% from pharmaceutical excipients, 3.16% from plant extracts and others, and 0.63% from technology transfer and services [1][1][1]

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-064 | 湖南九典制药股份有限公司 关于回购公司股份的进展公告 特此公告。 湖南九典制药股份有限公司董事会 2025 年 9 月 1 日 一、回购公司股份的进展情况 截至 2025 年 8 月 31 日，公司通过股份回购专用证券账户以集中竞价交易方 式累计回购股份 6,180,800 股，占公司目前总股本的 1.24%，最高成交价为 18.44 元/股，最低成交价为 14.51 元/股，成交总金额为 100,031,244 元（不含交易费 用）。本次回购符合相关法律法规及公司既定的回购方案。 二、其他说明 公司回购股份的时间、回购股份数量、集中竞价交易的委托时间及交易价格 等均符合《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的规定。 后续公司将在回购期限内，结合市场情况适时推进股份回购工作，并根据相 关法律法规及时履行信息披露义务，敬请投资者注意投资风险。 本公司及董事会全体成员保证向本公司提供的信息内容真实、准确、 ...

Core Viewpoint - The company, Jiutian Pharmaceutical, announced the completion of the phase III clinical trial summary report for its Pepper Seven Pain Relief Gel Patch [2] Group 1 - The announcement was made on the evening of September 1 [2] - The clinical trial report is a significant milestone for the company [2]

Core Viewpoint - Jiutian Pharmaceutical (300705.SZ) has recently obtained the summary report of the Phase III clinical trial for its Pepper Seven Pain Relief Gel Patch, which shows promising results for alleviating pain caused by knee osteoarthritis [1] Group 1: Product Efficacy - The Pepper Seven Pain Relief Gel Patch is effective in relieving pain associated with knee osteoarthritis [1] - The product acts quickly to improve clinical symptoms and the activity level of patients [1] - The medication is convenient to use and demonstrates good safety for patients [1] Group 2: Clinical Promotion - The positive results from the clinical trial suggest that the Pepper Seven Pain Relief Gel Patch is worthy of clinical promotion [1]

Core Viewpoint - The announcement from JiuDian Pharmaceutical indicates that the Phase III clinical trial report for the Pepper Seven Pain Relief Gel Patch shows significant efficacy in alleviating pain caused by knee osteoarthritis, with faster onset of pain relief compared to the placebo group [1] Summary by Relevant Categories Clinical Trial Results - The clinical trial results demonstrate that the treatment group showed significant differences in VAS pain score changes, pain relief rates, WOMAC total score changes, and overall effective rate of traditional Chinese medicine symptoms compared to the placebo group after 1 and 2 weeks of treatment [1] - The treatment group experienced a quicker onset of pain relief [1] Safety Profile - The drug exhibited a good safety profile, with only mild adverse reactions such as itching and skin burning sensation reported, and no serious adverse reactions occurred [1] Future Plans - The company plans to continue advancing the registration application for the drug, which will be available for market sale upon approval [1]

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-063 | 湖南九典制药股份有限公司 关于公司取得临床试验总结报告的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）近日取得椒七止痛凝胶贴 膏Ⅲ期临床试验总结报告。根据《深圳证券交易所上市公司自律监管指引第4号 ——创业板行业信息披露（2023年修订）》的相关要求，现将相关情况公告如下： 一、药物的基本情况 药物名称：椒七止痛凝胶贴膏（曾用名：椒七麝凝胶贴膏） 注册分类：中药1.1类 剂型：贴膏剂 功能主治：温经散寒，活血止痛 研究分期：Ⅲ期临床试验 二、临床试验结论 （1）疗效结论：椒七止痛凝胶贴膏能有效改善膝骨关节炎引起的疼痛，试 验组用药 2 周及 1 周后在目标侧膝关节 VAS 疼痛评分较基线变化值、止痛有效率、 WOMAC 总评分较基线变化值、中医证候总有效率方面均优于安慰剂组且有统计差 异，试验期间试验组的疼痛减轻起效 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady revenue growth, with a 10.67% year-on-year increase in revenue for the first half of 2025, reaching 1.512 billion yuan, and a net profit of 291 million yuan, up 2.57% year-on-year [5] - The company is actively enhancing its innovation pipeline, including the acquisition of the antibacterial peptide new drug JIJ02 gel for 90 million yuan, which is currently in clinical phase I and aims to treat common acne [6] - The company is undergoing a product structure adjustment, leading to revised profit forecasts for 2025-2027, with expected net profits of 570 million, 642 million, and 731 million yuan respectively [5] Financial Summary - For the first half of 2025, the gross margin was 74.58%, an increase of 1.44 percentage points, while the net margin was 19.27%, a decrease of 1.53 percentage points [5] - The company’s revenue from drug formulations in the first half of 2025 was 1.247 billion yuan, reflecting a 14.86% increase, with strong sales of products like Loxoprofen sodium gel patches [5] - The projected earnings per share (EPS) for 2025-2027 are 1.14, 1.28, and 1.46 yuan per share, with corresponding price-to-earnings (P/E) ratios of 16.2, 14.4, and 12.6 times [5][8]